Filtered By:
Condition: Bleeding
Therapy: Thrombolytic Therapy

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 159 results found since Jan 2013.

Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: a Review.
Abstract Primary cardiac tumors are uncommon, with an autopsy frequency of 0.001%-0.28%: 75% of them are benign, and 50-75% of these are myxomas. Often the first neurological manifestations of a cardiac myxoma include transient ischemic attacks and ischemic strokes. Although thrombolytic therapy represents the gold standard for acute ischemic stroke treatment, its safety and effectiveness in stroke patients with myxoma is unknown. From the analysis of the literature on thrombolysis in ischemic stroke patients with myxoma we report clinical evidence supporting the use of thrombolytics, and the application of thromb...
Source: Current Drug Safety - January 10, 2014 Category: Drugs & Pharmacology Authors: Acampa M, Guideri F, Tassi R, D'Andrea P, Marotta G, Giudice GL, Martini G Tags: Curr Drug Saf Source Type: research

The Reply
Intracranial bleeding with thrombolytic therapy in elderly patients with pulmonary embolism is far less frequent than death if unstable and thrombolytic therapy is withheld (42.6% mortality if untreated, aged 61-70, and no comorbid conditions vs 9.3% mortality with thrombolytic therapy; 47.0% mortality with comorbid conditions if untreated vs 21.6% if treated). In patients>65 years or with kidney disease, intracranial hemorrhage occurred in 1.4% with thrombolytic therapy. Intracranial hemorrhage with thrombolytic therapy in elderly patients with acute myocardial infarction also occurred in 1.4%. With ≥ 5 risk factors for...
Source: The American Journal of Medicine - October 22, 2013 Category: Journals (General) Authors: Paul D. Stein, Fadi Matta Tags: Letters Source Type: research

A multicenter, randomized, double‐blinded, placebo‐controlled phase III study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III)
BackgroundIn adults, intraventricular thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) facilitates resolution of intraventricular haemorrhage (IVH), reduces intracranial pressure, decreases duration of cerebrospinal fluid diversion, and may ameliorate direct neural injury. We hypothesize that patients with small parenchymal haematoma volumes (<30 cc) and relatively large IVH causing acute obstructive hydrocephalus would have improved clinical outcomes when given injections of low‐dose rtPA to accelerate lysis and evacuation of IVH compared with placebo. MethodsThe Clot Lysis Evaluation of Ac...
Source: International Journal of Stroke - August 1, 2013 Category: Neurology Authors: Wendy C. Ziai, Stanley Tuhrim, Karen Lane, Nichol McBee, Kennedy Lees, Jesse Dawson, Kenneth Butcher, Paul Vespa, David W. Wright, Penelope M. Keyl, A. David Mendelow, Carlos Kase, Christine Wijman, Marc Lapointe, Sayona John, Richard Thompson, Carol Thom Tags: Research Source Type: research

Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs
Thrombolytic therapy is the cornerstone of treatment of acute atherothrombotic ischemic stroke but is associated with brain hemorrhage; antiplatelet therapy has limited efficacy and is still associated with intracranial bleeding. Therefore, new antithrombotic approaches with a better efficacy/safety ratio are required. We have assessed the effect of ALX-0081, a Nanobody against the A1 domain of von Willebrand factor (VWF) that blocks VWF binding to GPIb, of the thrombolytic agent recombinant tissue plasminogen activator (rtPA), and of the GPIIb/IIIa antagonist tirofiban, in a middle cerebral artery (MCA) thrombosis model i...
Source: Blood - June 20, 2013 Category: Hematology Authors: Momi, S., Tantucci, M., Van Roy, M., Ulrichts, H., Ricci, G., Gresele, P. Tags: Platelets and Thrombopoiesis, Thrombosis and Hemostasis Source Type: research

Abstract 234: Prior Warfarin Treatment and Intracranial Hemorrhage among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator: A Meta-analysis Poster Session II
Conclusions: These data suggested that the risk of sICH after thrombolytic therapy is not increased in patients using warfarin with sub therapeutic INR levels.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Li, H., Xian, Y., Laskowitz, D., Peterson, E. Tags: Poster Session II Source Type: research

Intracranial hemorrhage due to pulmonary thromboembolism in heparin therapy and therapeutic management of patients hospitalized with massive pulmonary embolism after discharge.
Abstract A patient with a history of intracranial hemorrhage who was hospitalized due to massive pulmonary thromboembolism (PTE) was presented. A 59-year-old female patient had an intracranial hemorrhage while under anticoagulant therapy due to PTE after a knee operation. Therefore, the anticoagulant therapy was discontinued. Forty-seven days after the cessation of the anticoagulant treatment, the patient was admitted to the emergency department with a complaint of acute dyspnea and presyncope. Transthoracic echocardiography showed signs of right ventricular overload. Contrast-enhanced thorax computed tomography s...
Source: Turk Kardiyoloji Dernegi arsivi - May 1, 2013 Category: Cardiology Authors: Beşli F, Keçebaş M, Alişir MF, Güngören F Tags: Turk Kardiyol Dern Ars Source Type: research

The outcome of intra-aortic balloon pump support in acute myocardial infarction complicated by cardiogenic shock according to the type of revascularization: A comprehensive meta-analysis
Aims: Despite the recommendations of the current guidelines, scientific evidence continue to challenge the effectiveness of intra-aortic balloon pump (IABP) in acute myocardial infarction (AMI) complicated by cardiogenic shock. Moreover, 2 recent meta-analyses showed contrasting results. The aim of this study is to test the effect of IABP according to the type of therapeutic treatment of AMI: percutaneous coronary intervention (PCI), thrombolytic therapy (TT), or medical therapy without reperfusion. Articles published from January 1, 1986, to December 31, 2012, were collected and analyzed by meta-analysis.Methods and resul...
Source: American Heart Journal - March 27, 2013 Category: Cardiology Authors: Francesco Romeo, Maria Cristina Acconcia, Domenico Sergi, Alessia Romeo, Saverio Muscoli, Serafina Valente, Gian Franco Gensini, Flavia Chiarotti, Quintilio Caretta Tags: Curriculum in Cardiology Source Type: research

Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.
Abstract Intravenous recombinant human tissue plasminogen activato (rtPA, formulated as alteplase) is the primary therapy for acute ischaemic stroke by breaking down a clot of an occluded vessel. There are several randomised controlled trials and observational studies that support the use of rtPA to improve functional outcome following acute ischaemic stroke. However, thrombolytic therapy with rtPA can be associated with a number of complications. Many of the rtPA-related complications result from its thrombolytic action including bleeding (intracerebral and systemic haemorrhage), reperfusion injury with oedema, a...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Balami JS, Sutherland BA, Buchan AM Tags: CNS Neurol Disord Drug Targets Source Type: research

Thrombolytic Agents for Acute Ischaemic Stroke Treatment: the Past, Present and Future.
Abstract Despite advances in the diagnosis and treatment of acute ischaemic stroke in the past two decades, stroke has remained the third cause of mortality and the single leading cause of disability worldwide. The immediate goal of acute ischaemic stroke therapy is to salvage the ischaemic penumbra through recanalisation of the occluded cerebral blood vessel. This is currently achieved through thrombolytics, which are pharmacological agents that can break up a clot blocking the flow of blood. To date, the only approved thrombolytic for treatment of acute ischaemic stroke is recombinant tissue plasminogen activato...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Balami JS, Chen R, Sutherland BA, Buchan AM Tags: CNS Neurol Disord Drug Targets Source Type: research